@article{987fab92d93f4b26b7ddc0c2356b4e09,
title = "Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL",
author = "Patrick Brown and Gerhard Zugmaier and Lia Gore and Tuglus, {Catherine A.} and {von Stackelberg}, Arend",
note = "Funding Information: This work was supported by Amgen Inc. PB participated in advisory boards for Amgen, Novartis, Shire, and Jazz. GZ is an employee of Amgen GmbH and holds stock, patents and other intellectual property in Amgen. LG received advisory board/consulting fees from Amgen, Novartis Corp., Celgene Corp., and Roche/Genentech; has stock and stock options in Amgen, Anchiano, Clovis Oncology, Mirati, OnKure, and Sanofi Paris and is a member of the board of directors for Roundup River Ranch/SeriousFun Network. CAT is an employee of and holds stock/stock options in Amgen. AvS participated in advisory boards for Amgen, Roche, Shire, and Pfizer; and participated on the speakers{\textquoteright} bureaus for Amgen and Shire. ",
year = "2020",
month = feb,
day = "1",
doi = "10.1111/bjh.16306",
language = "English (US)",
volume = "188",
pages = "e36--e39",
journal = "British journal of haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",
}